Alphabet Inc. Acquires New Stake in Maze Therapeutics, Inc. $MAZE

Key Points

• Alphabet acquired 1.39 million Maze Therapeutics shares worth approximately $41.4 million, giving it a 2.51% stake in the clinical-stage biotech.
• Maze shares traded around $27.95, while the company reported a quarterly loss of $0.76 per share in line with estimates; analysts expect a full-year loss of $2.71 per share.
• Analyst sentiment remains mixed but averages a “Buy” rating with a $66 price target, while insiders have sold approximately 140,674 shares worth $3.9 million over the past three months.

Alphabet Inc. bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,388,583 shares of the company's stock, valued at approximately $41,435,000. Maze Therapeutics makes up about 0.0% of Alphabet Inc.'s investment portfolio, making the stock its 16th biggest position. Alphabet Inc. owned about 2.51% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Royal Bank of Canada lifted its position in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the 4th quarter valued at about $39,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the fourth quarter valued at approximately $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Maze Therapeutics in the 2nd quarter worth approximately $48,000.

Maze Therapeutics Trading Up 2.8%

NASDAQ MAZE opened at $27.95 on Tuesday. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a market cap of $1.55 billion, a PE ratio of -11.09 and a beta of 2.22. The company's 50-day moving average price is $27.88 and its 200-day moving average price is $32.83. Maze Therapeutics, Inc. has a 12 month low of $12.81 and a 12 month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). Equities research analysts forecast that Maze Therapeutics, Inc. will post -2.71 earnings per share for the current year.

Insider Transactions at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the sale, the insider owned 26,250 shares in the company, valued at approximately $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 140,674 shares of company stock valued at $3,904,707. Corporate insiders own 5.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on MAZE shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. BTIG Research restated a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of "Buy" and an average price target of $66.00.

Maze Therapeutics Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source